Montaño LAJ, Angulo P

Idioma: Español
Referencias bibliográficas: 51
Paginas: 62-68
Archivo PDF: 72.09 Kb.

RESUMEN

Los auto-anticuerpos representan una manifestación no patogénica de reactividad inmune que puede presentarse en las enfermedades agudas y crónicas del hígado y parecen ser consecuencia más que causa del daño hepático, por lo que deben utilizarse como herramientas de diagnóstico, más que marcadores etiológicos. Los auto-anticuerpos convencionales para el estudio de las enfermedades hepáticas son los anticuerpos anti-nucleares, anti-músculo liso, anti-microsomales de hígado/riñón tipo 1, anti-mitocondriales y anti-citoplasma de neutrófilos perinucleares. Sin embargo, el diagnóstico final y las estrategias de tratamiento no dependen solamente de estos marcadores serológicos. Los auto-anticuerpos son marcadores variables de acuerdo con el tiempo de su determinación y su comportamiento no se correlaciona con la actividad de la enfermedad. Su sobreinterpretación es el error más frecuente en la aplicación clínica de los resultados serológicos. El reconocimiento y la caracterización de nuevos auto-anticuerpos podrán mejorar la precisión diagnóstica, proveer índices pronóstico y elucidar nuevos auto-antígenos blanco para el manejo de las enfermedades hepáticas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-49.

2. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003; 37: 315-29.

3. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401.

4. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000; 343: 108-17.

5. Jaeckel E, Manns MP. Anti-nuclear and anti-histone auto-antibodies in autoimmune disease. J Gastroenterol Hepatol 1998; 13: 453-6.

6. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-6.

7. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004; 99: 1316-20.

8. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.

9. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93-151.

10. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997; 40: 1601-11.

11. Czaja AJ, Cassani F, Cataleta M, et al. Antinuclear antibodies and patterns of immunoflourescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997; 42: 1688-96.

12. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200-7.

13. Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122: 993-9.

14. Leung PSC, Coppel RL, Ansari A, et al. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 61-9.

15. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 79-90.

16. Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25: 298-310.

17. Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2: 1116-22.

18. Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 431-7.

19. Sternsdorf T, Guldner HH, Szostecki C, et al. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995; 42: 257-68.

20. Courvalin JC, Lassoued K, Bartnik E, et al. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990; 86: 279-85.

21. Courvalin JC, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990; 172: 961-7.

22. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.

23. Pedersen JS, Toh BH, Mackay IR, et al. Segregation of autoantibody to cytoskeletal filaments, actin and intermediate filaments with two types of chronic active hepatitis. Clin Exp Immunol 1982; 48: 527-32.

24. Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73.

25. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-8.

26. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-9.

27. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 1987; 7: 1333-9.

28. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.

29. Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1377-80.

30. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 705-11.

31. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.

32. Angulo P, El-Amin O, Carpenter HA, Lindor KD. Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. Am J Gastroenterol 2001; 96: 3021-7.

33. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis. A clue to its etiopathogenesis? J Hepatol 1992; 15: 6-9.

34. Moteki S, Leung PS, Coppel RL, et al. Use of a designer triple expression hybrid clone for three different lipoyl domains for the detection of antimitochondrial antibodies. Hepatology 1996; 24: 97-103.

35. Muratori P, Muratori L, Gershwin ME, et al. “True” anti-mitochondrial antibody-negative primary biliary cirrhosis: Low sensitive of the routine assays or both? Clin Exp Immunol 2004; 135: 154-8.

36. Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-17.

37. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-66.

38. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25: 1105-7.

39. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol 1996; 24: 581-6.

40. Czaja AJ. Auto-immune chronic active hepatitis: a specific entity? The negative argument. J Gastroenterol Hepatol 1990; 5: 343-51.

41. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.

42. Treichel U, Poralla T, Hess G, et al. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 1990; 11: 606-12.

43. Treichel U, Gerken G, Rossol S, et al. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 1993; 19: 55-63.

44. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-40.

45. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892-8.

46. Muratori L, Cataleta M, Muratori P, et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-6.

47. Montano-Loza A, Czaja AJ, Carpenter HA, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006; 39: 341-8.

48. Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 1995; 23: 32-8.

49. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-72.

50. Czaja AJ, Shums Z, Binder WL, et al. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003; 48: 1658-64.

51. Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol 1998; 93: 1334-9.